We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands ...

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The fund advanced 7.69% ...

Fintel reports that on May 2, 2025, Citigroup initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Buy recommendation. As of April 24, 2025, the average one ...

Investors with a lot of money to spend have taken a bullish stance on Structure Therapeutics (NASDAQ:GPCR). And retail traders should know. We noticed this today when the trades showed up on publicly ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Structure Therapeutics Inc. - Depositary Receipt () (NasdaqGM:GPCR) with a Outperform recommendation. As of February 19, ...

Through an international collaboration, scientists at St. Jude Children’s Research Hospital leveraged data science, pharmacology and structural information to conduct an atomic-level investigation ...

Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it’s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with ...

Scientists reveal how G protein-coupled receptors, major therapeutic drug targets, decode critical properties of their ligands. Through an international collaboration, scientists at St. Jude ...